Chairman & Officer Files Intent to Sell $1.27M in Shares Following Recent RSU Vesting and FDA Approval

summarizeSummary

Vanda Pharmaceuticals' Chairman and Officer, Mihael H. Polymeropoulos, filed an intent to sell $1.27 million worth of shares, acquired from RSU vesting, shortly after the company received FDA approval for a new drug.

check_boxKey Events

• Key Executive Files Intent to Sell

  Mihael H. Polymeropoulos, Chairman of the Board and an Officer, filed a Form 144 to sell 156,235 shares of common stock.

• Significant Transaction Value

  The proposed sale has an approximate market value of $1,276,976.00.

• Shares from RSU Vesting

  The shares intended for sale were acquired on March 1, 2026, through the vesting and settlement of Restricted Stock Units (RSUs) as compensation.

• Timing Post-FDA Approval

  This intent to sell follows the company's announcement of FDA approval for BYSANTI™ on February 23, 2026, a significant positive development.

auto_awesomeAnalysis

Mihael H. Polymeropoulos, the Chairman of the Board and an Officer, has filed a Form 144 indicating an intent to sell 156,235 shares of common stock, valued at approximately $1.27 million. These shares were acquired through the vesting and settlement of Restricted Stock Units (RSUs) on March 1, 2026. This significant insider selling intent, representing a notable portion of the company's market capitalization, comes shortly after the company announced FDA approval for BYSANTI™ on February 23, 2026, a major positive catalyst. While the sale is tied to compensation vesting, the timing of a key executive filing an intent to sell after such positive news could be viewed negatively by investors, adding to a recent pattern of insider distribution.